These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33349879)

  • 1. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery.
    Weil GJ; Jacobson JA; King JD
    Int Health; 2020 Dec; 13(Suppl 1):S60-S64. PubMed ID: 33349879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia.
    Supali T; Djuardi Y; Christian M; Iskandar E; Alfian R; Maylasari R; Destani Y; Lomiga A; Minggu D; Lew D; Bogus J; Weil GJ; Fischer PU
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009294. PubMed ID: 33780481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-drug therapy with ivermectin, diethylcarbamazine and albendazole for the acceleration of lymphatic filariasis elimination in Kenya: Programmatic implementation and results of the first impact assessment.
    Njenga SM; Kanyi H; Okoyo C; Githinji E; Mwatele C; Matendechero SH; Omondi WP; Gitahi PN; Owaga C; Onsongo JK; Gass K
    PLoS Negl Trop Dis; 2024 Jul; 18(7):e0011942. PubMed ID: 38976718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
    Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
    Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.
    Macfarlane CL; Budhathoki SS; Johnson S; Richardson M; Garner P
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD003753. PubMed ID: 30620051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
    Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
    PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned.
    Tripathi B; Roy N; Dhingra N
    Am J Trop Med Hyg; 2022 May; 106(5_Suppl):29-38. PubMed ID: 35292580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis.
    Weil GJ; Fischer PU; Krentel A
    Am J Trop Med Hyg; 2022 May; 106(5_Suppl):13-17. PubMed ID: 35292585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
    Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
    Clin Infect Dis; 2021 Sep; 73(6):994-1002. PubMed ID: 33728462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albendazole for lymphatic filariasis.
    Critchley J; Addiss D; Gamble C; Garner P; Gelband H; Ejere H;
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003753. PubMed ID: 16235339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings.
    James A; Coffeng LE; Blok DJ; King JD; de Vlas SJ; Stolk WA
    Clin Infect Dis; 2024 Apr; 78(Supplement_2):S131-S137. PubMed ID: 38662696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerating the Uptake of WHO Recommendations for Mass Drug Administration Using Ivermectin, Diethylcarbamazine, and Albendazole.
    King JD; Jacobson J; Krentel A
    Am J Trop Med Hyg; 2022 May; 106(5_Suppl):26-28. PubMed ID: 35292578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
    Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
    Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
    Fischer PU; King CL; Jacobson JA; Weil GJ
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005163. PubMed ID: 28056015
    [No Abstract]   [Full Text] [Related]  

  • 16. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.
    Weil GJ; Bogus J; Christian M; Dubray C; Djuardi Y; Fischer PU; Goss CW; Hardy M; Jambulingam P; King CL; Kuttiat VS; Krishnamoorthy K; Laman M; Lemoine JF; O'Brian KK; Robinson LJ; Samuela J; Schechtman KB; Sircar A; Srividya A; Steer AC; Supali T; Subramanian S;
    PLoS Med; 2019 Jun; 16(6):e1002839. PubMed ID: 31233507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007).
    Hooper PJ; Bradley MH; Biswas G; Ottesen EA
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S17-21. PubMed ID: 19843394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
    Horton J; Witt C; Ottesen EA; Lazdins JK; Addiss DG; Awadzi K; Beach MJ; Belizario VY; Dunyo SK; Espinel M; Gyapong JO; Hossain M; Ismail MM; Jayakody RL; Lammie PJ; Makunde W; Richard-Lenoble D; Selve B; Shenoy RK; Simonsen PE; Wamae CN; Weerasooriya MV
    Parasitology; 2000; 121 Suppl():S147-60. PubMed ID: 11386686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albendazole for lymphatic filariasis.
    Addiss D; Critchley J; Ejere H; Garner P; Gelband H; Gamble C;
    Cochrane Database Syst Rev; 2004; (1):CD003753. PubMed ID: 14974034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.